
Microorganisms and cancer: scientific evidence and new hypotheses

Velázquez, Encarna; Peix, Álvaro; Gomez-Alonso, Alberto

Published in Cir Esp.2011, 89 :136-44 - vol.89 No. 03

. Read in: Español

Download PDF in: Spanish - Español

. Abstract

Summary

The involvement of microorganisms in human cancer has been known for over a century and different types of parasites, bacteria and viruses have been implicated in oncogenic processes. Within the bacteria, was first recognized as carcinogenic *Helicobacter pylori*, which causes gastric cancer and may be related to extra gastric cancers in humans. *Helicobacter hepaticus* has been associated with liver cancer using animal models. Other bacteria, such as *Chlamydia*, *Borrelia burgdorferi* and *Streptococcus bovis*, have been associated with ocular tumors, skin and colorectal cancers, respectively. In addition, a human intestinal commensal bacteria, *Bacteroides fragilis*, has been linked recently with colorectal cancer using animal models.

Key words: Cancer. Microorganisms. Man.

Full Text

Introduction

The discovery that the disease producing organisms was one of the major milestones of microbiology in the nineteenth century and, at the end of that century, microbiologists have sought in these organisms the origin of many diseases, including cancer. Several authors have recently carried out reviews of the microorganisms that cause cancer in humans^{1, 2,3}, among which could be noted in Zur Hausen, winner of 2008 Nobel Prize in Medicine for his work on human papillomavirus and its implication in cancer⁴. Evidence that different parasites, viruses and bacteria are involved in human cancer are becoming more numerous (Table 1) and the latest research results indicate the need for further research into the role of microorganisms in cancer.

Table 1. Microorganisms that have been linked to various cancers

Location microbial species or host cancer

Vermin

Female Gallbladder *Schistosoma haematobium*

Liver *Opisthorchis viverrini* Man

Liver Female *Clonorchis sinensis*

Bacteria

Mouse Colorectal *Bacteroides fragilis*
Borrelia burgdorferi Leather Man
Ocular *Chlamydia psittaci* Man
Gastrointestinal Female *Helicobacter pylori*
Helicobacter pylori Eye Man
Helicobacter pylori Mama Man
Hepatobiliary *Helicobacter hepaticus* mouse and man may
Streptococcus bovis Small Man

Virus

Epstein-Barr virus (EBV) B cell lymphomas, Burkitt's lymphoma, nasopharyngeal cancer man
Kaposi sarcoma herpesvirus 8 Man
Cervical papillomavirus and different sexual organs Man
Hepatitis viruses B and C (HBV and HCV) Liver Man
HTLV-1 Leukemia Virus Man
Liver SV40 monkey, mouse and hamster
Virus mouse mammary tumor (MMTV) Mama Mouse
Parasites were first

The first human cancer-related microorganisms were different parasites⁴. Specifically, *Opisthorchis felinus* liver cancer, *Bilharzia* (schistosomiasis) and cancer *Spirocerca* *vejiga*⁷ lupi dog with granulomas can refer sarcomas⁸. Taking into account the results of all these and other studies, the IARC (International Agency for Research on Cancer) concluded that there is enough evidence to implicate in human cancer and *Schistosoma haematobium* *Clonorchis viverrini*⁹. *Schistosoma haematobium* is currently one of the leading causes of gallbladder cancer in Egypt and *Opisthorchis* and *Clonorchis sinensis* *viverrini* are important factors in cholangiocarcinomas and liver carcinomas in southeastern Thailand and southern China⁵.

After the virus

The following microorganisms involved in different types of tumors were virus⁴, 5, and in 1898 had published M'Faydan and Hobday transmission between animals¹⁰ warts. In 1911 Rous demonstrated the transmission of a solid tumor, sarcoma of the chicken, cells¹¹ free extracts. At this time, other viruses were related to the production of tumors in animals, such as mammary tumor virus rat¹², the poliovirus¹³, a virus that causes erythroblastosis in mouse liver and SV40 adult¹⁴ which, from liver monkeys, when inoculated into newborn hamsters, caused tumors in a few months *in vivo*¹⁵, 16. Although these tumors are not reproducing the virus, an antigen specific¹⁷ originated as was the case of tumors induced papillomavirus¹⁸.

In the case of man, the first oncogenic virus was described by Burkitt, a surgeon who worked in Africa and found lymphoma in children of certain areas geográficas¹⁹. Later it

was discovered that the cause was a virus²⁰ later called Epstein-Barr, mononucleosis infectiosa²¹ responsible. The development of immunological detection of viral antigens to the discovery high titers of antibodies in patients with lymphoma and carcinomas Burkitt²² nasofaríngeos²³.

In the 70's got the characterization of a virus isolated from myeloid leukemia aguda²⁴ and detected the presence of mammary tumor virus in mouse milk of women and mama²⁵ cancer. Later it was discovered the involvement of hepatitis B virus in hígado²⁶ cancer, retrovirus identified in a rare form of leukemia humana²⁷, it was discovered the involvement of papillomavirus in cervical cancer women^{4, 5}, the involvement of the virus hepatitis C and cancer hígado²⁸ herpesvirus 8 as the most likely agent Kaposi²⁹ sarcoma.

Bacteria after viruses

Although developed Bacteriology Virology long before the last microorganisms involved in human cancer were bacteria, and not until 1905 that published the first results on the isolation of bacteria from tumors, the surgeon called Doyen³⁰ *Micrococcus neoformans*. Even prepared a vaccine, he said, cured cancer and was applied by Wright, who described this vaccine cure a case of inoperable³¹ cancer. Wright's group observed that the characteristics of this bacterium were consistent with those of the genus *Staphylococcus*³². Obviously, the techniques of that time to cancer diagnosis or identification of bacteria were not confident enough to engage *Staphylococcus* bacteria in cancer, even causing infections in patients with cáncer^{33, 34}, has been isolated, together with other bacteria, in solid tumors, such as mama³⁵.

The interest aroused by the involvement of various viruses in different cancers relegated the study of bacteria in these diseases into the background and, to the late twentieth century, no bacteria was clearly related to the production of tumors, with *Helicobacter pylori* first bacterium known to be carcinogenic to humans. His involvement in gastric cancer was discovered in 1991^{36,37,38,39} and in 1994 was recognized H. carcinogénico⁹ *pylori* agent. Some years later it was discovered that the ability to produce gastric cancer was related to the presence of certain regions in the genome of the bacterium, called pathogenicity islands because their ends are directly repeated DNA sequences that set them apart from the rest of the genome. These regions are absent in nonpathogenic strains, which may acquire by transfer genética^{40, 41}. The islands belong to *Helicobacter pylori* secretion system IV^{42, 43}, present in other pathogenic bacteria such as *Agrobacterium tumefaciens*, responsible for tumor formation in plants superiores⁴⁴.

Since the discovery of the involvement of H. *pylori* in gastric cancer, several bacteria have been identified in various tumor types, but has not yet been shown to be the direct cause of carcinogenesis, as in the case of *Chlamydia psittaci* and various types of cancers oculares⁴⁵, *Borrelia burgdorferi* and piel⁴⁶ lymphomas, different species of *Streptococcus* and colon cancer and other cancers digestivos^{47, 48} and, finally, between *Bacteroides fragilis* and colorrectal⁴⁹ cancer.

Koch's postulates in cancer

Already in the twenty-first century research on bacteria possibly involved in cancer has continued, although basically centered on *Helicobacter pylori*, on which there are numerous recent reviews publicadas^{50, 51, 52}. Prove that a microorganism is capable of inducing cancer is difficult because an infectious agent may trigger the initial events of oncogenesis but absent in the tumor final^{1, 5}. Since Robert Koch enunciated his famous postulates that must be met to ensure that a microorganism is responsible for an infectious process, only in the case of *Helicobacter pylori* have been demonstrated in man and only in the case of gastritis. And yet, since it was first observed in the human gut bacteria linked to Marshall showed úlceras⁵³ until Koch's postulates had to spend more than a siglo⁵⁴. However, the recognition of this bacterium as carcinogenic class I got only 9 years tarde⁹. Today, Koch's postulates can only be met using animal models, but often can not even isolate the organism responsible and must be used to study microbial genes present in cancerous tissue samples. Therefore, it might be convenient to redefine the Koch's postulates when microorganisms may not be present in tumors at the time of detection.

Bacteria involved in gastrointestinal cancer

After two decades of research, is now fully accepted the role of *H. pylori* in certain types of gastric cancer and therapy for the eradication of bacteria is part of the treatment of these cánceres^{55, 56, 57}. Numerous studies have been conducted to try to establish the specific mechanisms of interaction of this bacterium with hombre^{58, 59}, his virulencia⁶⁰ factors, ⁶¹ and the secretion system to which belong the islands of patogenicidad^{62, 63}. It has been shown that the risk of gastric cancer caused by *H. pylori* is increased in patients infected with strains carrying the *cagA* gene located on an island patogenicidad⁶⁴. However, the wide distribution of this island in the population infected with *H. pylori* casts doubt on these findings, it seems that there are differences between the types of cancers, most notably a relationship of strains carrying the island with gastric tumors with morphological similarity with the related intestinal tissue p⁵³ mutations found in cancer intestino⁶⁵. However, in diffuse-type gastric cancers are involved in both strains carrying the island and those who did not contienen⁶⁶. In addition certain alleles of *vacA* gene, involved primarily in gastritis, are also associated with cancer gástrico^{67, 68}. Although variations have been found in the sequences of the genes of the *cag* island of *H. pylori* in some populations, which could impede its use in the diagnosis of virulent strains of this bacteria^{69, 70}, what does seem clear is that the presence of the entire island in *H. pylori* is associated with gastric symptoms more intensos⁷¹. Very recently it has also confirmed that gastrin is an essential cofactor of gastric cancers induced by *H. animales*⁷² *pylori* models.

Taking into account the severity and the increase of gastric cancer in the last decade in some regions of mundo⁷³, including that produced by *H. pylori* eradication has been proposed for this bacterium in all patients in whom this is found, but has not developed cancer, as this is a long process, in the early stages may manifest only as a atrofíca⁷⁴

gastritis and have been shown to cure virtually all patients with gastric lymphoma MALT57 type. However, other types of gastric cancer, eradication of this bacterium only gets reduced by one third its prevalence75. Furthermore, the eradication of this bacteria is not achieved in all cases and patients infected with strains carrying the pathogenicity islands present greater *vacA* and *cagA* eradication61 failure. Thus, we have conducted numerous studies on the mechanisms involved in host immune response to the infection76 to facilitate the development of a vaccine to prevent cancers caused by *Helicobacter pylori*77.

Taking into account the relationship of *H. pylori* with stomach cancer, has raised the possible involvement of this bacterium in cancer-related bodies digestive system, as has been found in bile and gallbladder, postulating the involvement of *H. pylori* in the liver and kidney cancers in hombre78. However, more detailed studies and more standardized protocols to detect bacterial DNA or anti-*Helicobacter* bacteria in order to relate this with biliar79 tract cancers, 80. Several studies have found DNA from *H. pylori* in human liver carcinomas, but in some cases not established the exact species of *Helicobacter* present in mismos81, 82.83. Another species of the genus *Helicobacter*, *H. hepaticus*, has been implicated in hepatobiliary cancer animales78 models, 79,84,85. Very recently, using techniques of molecular biology and immunology have described the presence of *H. gallbladder hepaticus* in patients with various digestive ailments, including cancer gástrico86. With regard to pancreatic cancer, the results are contradictory, although it has found a positive relationship between the presence of *H. pylori* and this type of tumors in non-smokers or bebedores87. In the case of the esophagus and larynx results indicate no association with this bacteria88, 89.

The increased risk of colorectal cancer has been linked to infection with various microorganismos90, including bacteria include *H. Streptococcus bovis*92 *pylori*91 and in man, and *H. hepaticus* in ratón93. However, further studies are needed to elucidate whether the latter species can cause cancers such humanos94. In the case of *Streptococcus bovis*, their relationship with colorectal cancer is well established since the mid-7047.95, although currently some strains of this species have been reclassified in *S. infantarius* and *S. gallolyticus*96. According to epidemiological studies have found a very high in the case of *S. gallolyticus* colon cancer, while *S. infantarius* has higher correlation with cancers of other organs related to digestive system, such as pancreatic duct and biliares96. Other very recent studies have found that *S. gallolyticus* plays an essential role in the progression of normal colorectal mucosa, adenoma and cancer a colorrectal97. Since endocarditis caused by *Streptococcus* are associated with cancer colorrectal47, 48.95, has been proposed that colonoscopy should be mandatory in cases of endocarditis caused by these microorganismos98.

In addition to these bacteria has recently been published tumor induction by *Bacteroides fragilis*, an intestinal commensal bacteria from man, whose role in colorectal cancer could be similar to that of *H. pylori* in gastric cancer. It has been shown that enterotoxigenic strains of these bacteria produce colitis and induce the formation of tumors in the colon of mice via activation of T helper type lymphocytes may be involved in the production of cancer also humanos49.

Bacteria involved in extra gastric cancers

Although the first bacterium described as cancer-producing agent may correspond to *Staphylococcus aureus* and some authors have attempted to relate mama32 cancer has never been shown their involvement in human cancer, even in a recent study using cell cultures have shown that an extracellular protein involved in the adherence of *S. aureus* can prevent cancer bone metastases mama99. However, recently there have been reports of infection with *S. aureus* concomitant with breast cancer that is not very clear the relationship between the two enfermedades100. In addition, recently described the presence of human papillomavirus type 16 (HPV-16) in the genomes of different bacteria, including *Staphylococcus aureus*, isolated from cervix101 cancer. The authors suggest that the presence of these viruses in the bacterial genome could explain the progression of an infection with HPV-16 in cervical cancer using the bacterium as vector101.

Recent research has also linked to *H. pylori* extra gastric cancers, including lung and mama102, 103.104 mainly via induction of gastrin, which, apart from a hormone, a factor involved in carcinogenesis, tumor growth and metastasis of these two types of tumores102, 103. Together, stress and mast cells located in the BBB can trigger a series of reactions that facilitate the development of brain metastases from lung tumors and mama105. *H. pylori* is involved in this process and has proposed that its eradication may prevent this type of metastasis cerebrales106.

The presence of *Borrelia burgdorferi* DNA in lymphomas has led some to suggest a relationship of this bacterium with non-cutaneous Hodgkin46. The bacteria can survive in the skin of patients for decades and occasionally can develop B cell lymphomas and, additionally, other type neoplasia carcinoma, so it has proposed a relationship of *B. burgdorferi* with this type of tumores107.

In recent years also been associated with different bacteria ocular108 cancers among which we highlight *H. pylori* and *Chlamydia*. In MALT ocular tumors have found conflicting results regarding the involvement of *H. pylori*, as some studies suggest an involvement of this bacteria109, 110, while others show negativos111 results. It seems that *Chlamydia* is most probably involved in eye cancers and has proposed its elimination, along with that of *H. pylori*, as pretreatment therapies agresivas46, 109. *Chlamydia psittaci* is the only species identified by the time type MALT109 ocular tumors, 111.112, and some authors have found differences geográficas111, being positive relationship between this bacterium and ocular cancers and negative Austria112 Italia46 and Unidos113 States. It is thought that these discrepancies may be due to the methodology used for the detection of bacterias114. Some authors have found that other species, *Chlamydia trachomatis*, may be a risk factor when it coexists with some types of human papillomavirus carcinomas115. In the case of ovarian cancer appears that this bacterium could induce an inflammatory response that would lead to different types of cancer, although the authors recommend further studies amplios116.

Metagenomics, a new way of detecting tumor-producing bacteria

It is now recognized that bacteria may be involved in different types of cancers, but not easy to detect¹ due to multiple reasons, including the fact that cancer is not the result of an acute infection and thus the causal agent can not recover from tumor⁵. However, viral or bacterial DNA may persist for some time, either in the tumor itself, either in the peritumoral area, so that molecular techniques based on the amplification of bacterial DNA in tumor tissues are the most commonly applied for detection and identification of bacteria in tumors. Even techniques have been proposed based detection "find" the exogenous DNA sequences corresponding to the tumor after sequencing DNA fragments mismo^{117, 118, 119}. It is seldom necessary to assume that they will be able to fulfill Koch's postulates, because although disposes of pure cultures, confirmation of the carcinogenic potential of microorganisms must be obtained in animal models, as has happened recently in the case of the bacteria *Bacteroides fragilis*, whose role is carcinogenic in man assumed from the findings in rat⁴⁹.

Molecular biology techniques that allow the identification of microorganisms in the absence of insulation is known as metagenomics and are based on the amplification of microbial genes directly from a sample, whose subsequent sequencing allows the identification of microorganisms present in the misma^{120, 121}. Some metagenomic techniques have the advantage of allowing analysis of microorganisms in complex ecosystems such as cavity or intestino¹²³ oral¹²². To analyze these samples can be applied several techniques, such as DGGE¹²⁴ or SSCP¹²⁵, respectively based on the different electrophoretic mobility changes in the pattern of distortion or secondary formation of DNA single strand 16S ribosomal gene, whose sequence is the basis for classification and identification of bacteria. However, for the analysis of complex populations are especially useful intergenic spaces located between the 16S and 23S ribosomal genes (ITS) in bacteria and between 18S and 28S genes in fungi, which can be separated electrophoretically in a technique called RISA (ribosomal intergenic spacer analysis). Since the size of the ITS in bacteria is highly variable, RISA technique permits the separation of the ITS of most bacterianos¹²⁶ groups. The subsequent sequencing of the separated fragments allows identification of bacteria, as they are sequenced in all pathogenic bacteria and major hombre¹²⁶ diners. Using this technique we have analyzed the intestinal bacterial populations in individuals affected by cancer and laringe¹²⁶ colorrectal¹²⁷.

Metagenomic techniques have the advantage of allowing identification of cultivated and uncultivated microorganisms present in the human microbiome both healthy subjects and those affected by processes tumorales^{128, 129}. During these are changes in the microbiome resulting from the process itself tumoral¹²⁹ for antibióticos¹³⁰ treatments, ¹³¹ or radiation treatments and quimioterápicos^{130, 132}. Therefore, metagenomics is the most promising tool in the investigation of the microorganisms present in tumors, since new massive sequencing techniques (next-generation sequencing) enable the analysis of millions of sequences in record time and at competitive prices. There is no doubt that this type of techniques that allow the detection of microbial genes in any sample, contribute substantially to the knowledge of the microorganisms involved in the

production of tumors.

Conflict of interest

The authors declare no conflicts of interest.

Received January 14, 2010

Accepted August 3, 2010

Author for correspondence. agam@usal.es

Bibliography

1. Dalton-Griffin L, Kellam P. Infectious Causes of Cancer and Their detection. *J Biol* 2009; 8:67.
2. Martel C, Franceschi S. Infections and cancer: Established Associations and New Hypotheses. *Crit Rev Oncol Hematol*. 2009, 70:183-94.
3. Ziegler JL, FM Buonaguro. Infectious agents and human malignancies. *Frontiers Biosci*. 2009, 14:3455-64.
4. Zur Hausen H. *Infections Causing Human Cancer*. 2006. Germany: Wiley-VCH Verlag GmbH & Co, 2006.
5. Zur Hausen H. The search for infectious Causes of Human Cancers: where and why (Nobel lecture). *Angew Chem Int Ed Engl*. 2009, 48:5798-808.
6. Askanazy M. Des Menschen mit über Distomum infektion felineum (sibiricum) in Ostpreussen und mit ihren Zusammenhang Leberkrebs. *Bakt Cent Orig*. 1900, 28:491-502.
7. Goebel C. Über die mit Blasentumoren biennial Besonderer Bilharziakrankheit Berücksichtigung vorkommenden des Carcinoms. *Krebsforsch Zeitschr*. 1905, 3:369-513.
8. WAS Bailey. Parasites and cancer: sarcoma in dogs associated with *Spirocerca lupi*. *Ann N Y Acad Sci* 1963, 108:890-923.
9. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June schistosomes, liver flukes and *Helicobacter pylori*. *IARC Monogr Eval carcinogenicity Risks Hum*. 1994, 61:1-241.
10. M'Faydan J, Hobday F. Note on the experimental transmission of warts in the dog. *J Comp Pathol There*. 1898, 11:341-4.
11. Rous P. A sarcoma of the fowl transmissible by agent separable from Tumour cells. *J Exp Med* 1911, 13:397-411.
12. JJ Bittner. Some possible effects of nursing on the mammary gland tumor Incidence in mice. *Science*. 1936, 84:162.
13. Stewart SE. Polyoma virus carcinogenesis. *Acta Unio Int Contra cancrum*. 1963, 19:255-62.
14. Friend C. Cell-free transmission in adult Swiss mice of a disease HAVING the character of a leukemia. *J Exp Med* 1957, 105:307-18.
15. Eddy BE, Grubbs GE, Young RD. Tumor immunity in hamsters infected with adenovirus type 12 or simian virus 40. *Proc Soc Exp Biol Med* 1964; 117:575-9.
16. Girardi AJ, Sweet BH, Slotnick VB, Hilleman MR. Development of Tumors in

- hamsters in the Neonatal Period Inoculated with vacuolating virus, SV-40. *Proc Soc Exp Biol Med* 1962; 109:649-60.
17. Black PH, WP Rowe, HC Turner, Huebner RJ. A specific complement-fixing antigen present in SV40 tumor and Transformed cells. *Proc Natl Acad Sci U S A*. 1963, 50:1148-56.
 18. Habel K. Specific complement-fixing antigens in polyoma Tumors and Transformed cells. *Virology*. 1965, 25:55-61.
 19. Burkitt D. A children's cancer dependent on climatic factors. *Nature*. 1962, 194:232-4.
 20. Epstein MA, Achong BG, Barr YM. Hair-Spray. *Lancet*. 1964, 1:709-10.
 21. Henle G, Henle W, Diehl V. Relation of Burkitt's tumor-associated herpes-virus to infectious mononucleosis type. *Proc Natl Acad Sci U S A*. 1968, 59:94-101.
 22. Henle W, Hummel K, Henle G. Antibody coating and agglutination of virus Particles Separated from the EB3 line of Burkitt lymphoma cells. *J Bacteriol*. 1966, 92:269-71.
 23. Old LJ, Boyse EA, Oettgen HF, De Harven E, Geering G, Williamson B, et al. Precipitating antibody in human serum to an antigen present in cultured Burkitt's lymphoma cells. *Proc Natl Acad Sci USA*. 1966, 56:1699-705.
 24. Gallagher RE, Gallo RC. Type C RNA tumor virus isolated from cultured acute myelogenous leukemia human cells. *Science*. 1975, 187:350-3.
 25. MR Das, Vaidya AB, Sirsat SM, Moore DH. RNA Polymerase and studies on milk virions from women of the Parsi community. *J Natl Cancer Inst* 1972; 48:1191-6.
 26. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. *Lancet*. 1981, 2:1129-33.
 27. Hinum Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. *Proc Natl Acad Sci U S A*. 1981, 78:6476-80.
 28. Simonetti RG, Cottone M, Craxi A, Pagliaro L, Rapisetta M, Chionne P, et al. Prevalence of antibodies to hepatitis C virus in hepatocellular carcinoma. *Lancet*. 1989, 2:1338.
 29. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science*. 1994, 266:1865-9.
 30. Doyen TA. On the aetiology and Treatment of Cancer. *Edinburgh Med J*. 1905, 17:373-8.
 31. Spicer S, Wright AE. Case of inoperable cancer of the mouth, the pharynx, the tongue and the cervical glands have Shown That Marked amelioration After ten weeks Treatment for bacterial vaccine to With A neoformans. *J Laryngol*. 1906, 21:265-9.
 32. Wainwright M. Highly pleomorphic staphylococci as a cause of cancer. *Med Hypotheses*. 2000, 54:91-4.
 33. Felipe WA, Werneck GL, Santoro-Lopes G. Surgical site Infection Among Women With A drain discharge after-situ breast cancer surgery. *World J Surg*. 2007, 31:2293-9.
 34. Fukushima T, Kasai Y, Kato K, Fujisawa K, Uchida A. Intradural squamous cell carcinoma in the sacrum. *World J Surg Oncol*. 2009; 7:16.
 35. Brook I. Bacteria from Solid Tumours. *J Med Microbiol*. 1990, 32:207-10.
 36. Forman D. *Helicobacter pylori* Infection: a novel factor in the etiology Risk of gastric cancer. *J Natl Cancer Inst* 1991; 83:1702-3.

37. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. *Helicobacter pylori* Infection and gastric carcinoma Among Japanese Americans in Hawaii. *N Engl J Med* 1991; 325:1132-6.
38. Parsonnet J, Vandersteen D, Goates J, Sibley RK, Pritikin J, Chang Y. *Helicobacter pylori* Infection in intestinal-and diffuse-type gastric adenocarcinomas. *J Natl Cancer Inst* 1991, 83:640-3.
39. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. *Helicobacter pylori*-associated gastritis and primary gastric B-cell lymphoma. *Lancet*. 1991, 338:1175-6.
40. Gal-Mor O, Finlay BB. Pathogenicity islands: a molecular toolbox for bacterial Virulence. *Cell Microbiol*. 2006, 8:1707-19.
41. Juhas M, van der Meer JR, Gaillard M, Harding RM, Hood DW, Crook DW. Genomic islands: tools of bacterial horizontal gene transfer and evolution. *FEMS Microbiol Rev*. 2009; 33:376-93.
42. MJ Oliveira, Costa AC, Costa AM, Henriques L, Suriano G, Atherton JC, et al. *Helicobacter pylori* induces gastric epithelial cell invasion in a c-Met and type IV secretion system-dependent Manner. *J Biol Chem* 2006; 281:34888-96.
43. DM Pinto-Santini, Salama NR. Cag3 is a novel essential component of the *Helicobacter pylori* Cag Type IV secretion system outer membrane subcomplex. *J Bacteriol*. 2009, 191:7343-52.
44. Juhas M, Crook DW, DW Hood. Type IV secretion systems: tools of bacterial horizontal gene transfer and Virulence. *Cell Microbiol*. 2008, 10:2377-86.
45. Ferreri AJ, Ponzoni M, Guidoboni M, De Conciliis C, Resti AG, Mazzi B, et al. Ocular adnexal lymphoma Regression of *Chlamydia psittaci*-eradicating After antibiotic therapy. *J Clin Oncol*. 2005, 23:5067-73.
46. Schöllkopf C, Melbye M, Munksgaard L, Smedby KE, Rostgaard K, Glimelius B, et al. *Borrelia* Infection and Risk of non-Hodgkin lymphoma. *Blood*. 2008, 111:5524-9.
47. Klein RS, Recco RA, Catalano MT, Edberg SC, Casey JI, Steigbigel NH. Association of *Streptococcus bovis* with carcinoma of the colon. *N Engl J Med* 1977; 297:800-2.
48. Kim SY, Joo IS, Yi J, Kim EC. A Case of *Streptococcus gallolyticus* subsp. *gallolyticus* infective endocarditis with colon cancer: identification by sequencing 16S ribosomal DNA. *Korean J Lab Med* 2010; 30:160-5.
49. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, et al. A human colonic commensal colon tumorigenesis via activation Promotes T helper type of T cell responses 17. *Nat Med* 2009; 15:1016-22.
50. Costa AC, Figueiredo C, Touati E. Pathogenesis of *Helicobacter pylori* Infection. *Helicobacter*. 2009, 14:15-20.
51. Hatakeyama M. *Helicobacter pylori* and gastric carcinogenesis. *J Gastroenterol*. 2009, 44:239-48.
52. Suzuki H, Iwasaki E, Hibi T. *Helicobacter pylori* and gastric cancer. *Gastric Cancer*. 2009, 12:79-87.
53. Bottcher A. Zur Genese des perforierenden Magengeschwurs. *Medizinische Dopater Zeitschrift*. 1874, 5:148.
54. Marshall BJ, Armstrong JA, McGeachie DB, Glancy RJ. Attempt to Koch's postulate FulFil for pyloric *Campylobacter*. *Med J Aust*. 1985, 142:436-9.
55. Fucci L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can *Helicobacter pylori* Eradication Treatment reduces the Risk for gastric

cancer?. *Ann Intern Med* 2009; 151:121-8.

56. Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early *Helicobacter pylori* Eradication Decrease Risk of gastric cancer in Patients with peptic ulcer disease. *Gastroenterology*. 2009, 137:. 1641.e1-1648.e2

57. Zullo A, Hassan C, Andriani A, Cristofari F, De Francesco V, Ierardi E, et al. Eradication therapy for *Helicobacter pylori* in gastric MALT lymphoma Patients with: a pooled data analysis. *Am J Gastroenterol*. 2009, 104:1932-7.

58. Beswick EJ, Suarez G, Reyes VE. H. *pylori* and Host Interactions That Influence pathogenesis. *World J Gastroenterol*. 2006, 12:5599-605.

59. Amieva MR, El-Omar EM. Host-Bacterial Interactions in *Helicobacter pylori* Infection. *Gastroenterology*. 2008, 134:306-23.

60. Romano M, Ricci V, Zarrilli R. Mechanisms of disease: *Helicobacter pylori*-related gastric carcinogenesis - Implications for chemoprevention. *Nat Clin Pract Gastroenterol Hepatol*. 2006, 3:622-32.

61. Sugimoto M, Yamaoka Y. Virulence factor genotypes of *Helicobacter pylori* Eradication Affect cure rates of therapy. *Arch Exp Immunol Ther (Warsz)*. 2009, 57:45-56.

62. Bourzac KM, Guillemin K. *Helicobacter pylori*-host cell by type IV Interactions mediated secretion. *Cell Microbiol*. 2005, 7:911-9.

63. Snaith A, El-Omar EM. *Helicobacter pylori*: host genetics and disease outcomes. *Expert Rev Gastroenterol Hepatol*. 2008, 2:577-85.

64. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the Relationship Between *cagA* seropositivity and gastric cancer. *Gastroenterology*. 2003, 125:1636-44.

65. Shibata A, Parsonnet J, Longacre TA, Garcia MI, Puligandla B, Davis RE, et al. *CagA* status of *Helicobacter pylori* Infection and p53 Gene Mutations in gastric adenocarcinoma. *Carcinogenesis*. 2002, 23:419-24.

66. Parsonnet J, Friedman GD, Orentreich N, Vogelmann H. Risk for gastric cancer in *CagA* positive or People with *CagA* negative *Helicobacter pylori* Infection. *Gut*. 1997, 40:297-301.

67. Garza-Gonzalez E, Bosques-Padilla FJ, Perez-Perez GI, Flores-Gutierrez JP, Tijerina-Menchaca R. Association of gastric cancer. HLA-DQA1, and Infection with *Helicobacter pylori* *CagA* + and *VacA* + in a Mexican Population. *J Gastroenterol*. 2004, 39:1138-42.

68. Basso D, Zambon CF, Letley DP, Stranges A, Marchetti A, Rhead JL, et al. Clinical relevance of *Helicobacter pylori* *cagA* and *vacA* gene polymorphisms. *Gastroenterology*. 2008, 135:91-9.

69. Baghaei K, Shokrzadeh L, F Jafari, Dabiri M, Yamaoka Y, Bolfion M, et al. Determination of *Helicobacter pylori* Virulence by analysis of the *cag* pathogenicity island isolated from Iranian Patients. *Dig Liver Dis*. 2009, 41:634-8.

70. Ali M, Khan AA, Tiwari SK, Ahmed N, Rao LV, Habibullah CM. Association Between pathogenicity island *cag*-*Helicobacter pylori* in peptic ulcer from isolated, gastric carcinoma, non-ulcer dyspepsia and subjects with histological changes. *World J Gastroenterol*. 2005, 11:6815-22.

71. Talarico S, Gold BD, J Fero, DT Thompson, Guarner J, Czinn S, et al. Pediatric *Helicobacter pylori* isolated display distinct gene coding Capacities and Virulence gene

marker profiles. *J Clin Microbiol.* 2009, 47:1680-8.

72. Takaishi S, Tu S, Dubeykovskaya ZA, Whary MT, Muthupalani S, Rickman BH, et al. Gastrin is an essential cofactor for *Helicobacter*-associated gastric carcinogenesis corpus in C57BL / 6 mice. *Am J Pathol.* 2009, 175:365-75.

73. Quiros RM, Bui CL. Multidisciplinary approach to esophageal and gastric cancer. *Surg Clin North Am* 2009; 89:79-96.

74. Graham DY, Asaka M. Eradication of gastric cancer and more efficient surveillance gastric cancer in Japan: two peas in a pod. *J Gastroenterol.* 2010, 45:1-8.

75. Ito M, Takata S, Tatsugami M, Wada Y, Imagawa S, Matsumoto Y, et al. Clinical prevention of gastric cancer by *Helicobacter pylori* Eradication Therapy: a Systematic Review. *J Gastroenterol.* 2009, 44:365-71.

76. Suarez G, Reyes VE, Beswick EJ. Immune response to *H. pylori*. *World J Gastroenterol.* 2006, 12:5593-8.

77. Del Giudice G, Malfertheiner P, Rappuoli R. Development of vaccines Against *Helicobacter pylori*. *Expert Rev Vaccines.* 2009, 8:1037-49.

78. Pandey M, Shukla M. *Helicobacter* species are associated with possible Increase in Risk of Hepatobiliary Cancers tract. *Surg Oncol.* 2009, 18:51-6.

79. Martel C, Plummer M, Parsonnet J, van Doorn LJ, Franceschi S. *Helicobacter* species in Cancers of the extrahepatic biliary tract and gallbladder. *Br J Cancer.* 2009, 100:194-9.

80. Xuan SY, Xin YN, Chen AJ, Dong QJ, Qiang X, Li N, et al. Association Between the Presence of *H. pylori* in the liver and hepatocellular carcinoma: a meta-analysis. *World J Gastroenterol.* 2008, 14:307-12.

81. Abu Al-Soud W, Stenram U, Ljungh A, Tranberg KG, Nilsson HO, Wadström T. DNA of *Helicobacter* spp. and common gut bacteria in primary liver carcinoma. *Dig Liver Dis.* 2008, 40:126-31.

82. Avenaud P, Marais A, Monteiro L, Le Bail B, Bioulac Sage P, Balabaud C, et al. Detection of *Helicobacter* species in the liver of Patients with primary liver carcinoma and Without. *Cancer.* 2000, 89:1431-9.

83. Pellicano R, Mazzaferro V, Grigioni WF, Cutufia MA, Fagoonee S, Silengo L, et al. *Helicobacter* species sequences in liver samples from Patients with hepatocellular carcinoma and Without. *World J Gastroenterol.* 2004, 10:598-601.

84. Diwan BA, Sipowicz M, Logsdon D, Gorelick P, Anver MR, Kasprzak KS, et al. Marked liver tumorigenesis by *Helicobacter hepaticus* Requires Perinatal exposure. *Environ Health Perspect.* 2008, 116:1352-6.

85. Canella KA, Diwan BA, Gorelick PL, Donovan PJ, Sipowicz MA, Kasprzak KS, et al. Liver tumorigenesis by *Helicobacter hepaticus*: Considerations of mechanism. *In Vivo.* 1996, 10:285-92.

86. Hamada T, Yokota K, Ayad K, Hirai K, Kamada T, Haruma K, et al. Detection of *Helicobacter hepaticus* in human bile samples of Patients with biliary disease. *Helicobacter.* 2009, 14:545-51.

87. Lindkvist B, Johansen D, Borgström A, Manje J. A prospective study of *Helicobacter pylori* in relation to the Risk for pancreatic cancer. *BMC Cancer.* 2008, 8:321.

88. Masoud N, Manouchehr K, Najmeh D, Monireh H. Lack of association Between *Helicobacter pylori* and laryngeal carcinoma. *Asian Pac J Cancer Prev* 2008; 9:81-2.

89. Rezaii J, Tavakoli M, Esfandiari K, Ashegh H, Hasibi M, Ghanei G, et al. Association

- Between *Helicobacter pylori* Infection and Laryngo-hypopharyngeal carcinoma: a case-control study and review of the literature. *Head Neck*. 2008, 30:1624-7.
90. AN Burnett-Hartman, Newcomb PA, Potter JD. Infectious agents and colorectal cancer: a review of *Helicobacter pylori*, *Streptococcus bovis*, JC virus, and human papillomavirus. *Cancer Epidemiol Biomarkers Prev* 2008; 17:2970-9.
91. Zhao YS, Wang F, Chang D, Han B, You DY. Different Meta-analysis of test indicators: *Helicobacter pylori* Infection and the Risk of colorectal cancer. *Int J Colorectal Dis*. 2008, 23:875-82.
92. Boleij A, Schaeps RM, H. Tjalsma Association Between *Streptococcus bovis* and colon cancer. *J Clin Microbiol*. 2009, 47:516.
93. CM Nagamine, JJ Sohn, BH Rickman, AB Rogers, JG Fox, DB Schauer. *Helicobacter hepaticus* Infection Promotes colon tumorigenesis in the Apc BALB/c-Rag2 (-/-) (Min / +) mouse. *Infect Immun*. 2008, 76:2758-66.
94. Pellicano R, Ménard A, Rizzetto M, Mégraud F. *Helicobacter* species and liver diseases: association or causation?. *Lancet Infect Dis*. 2008, 8:254-60.
95. Steinberg D, Naggar CZ. *Streptococcus bovis* endocarditis with carcinoma of the colon. *N Engl J Med* 1977; 297:1354-5.
96. Corredoira J, Alonso MP, Chur A, Varela J. Association Between *Streptococcus infantarius* (Formerly *S. bovis* II / 1) Bacteremia and Noncolonic Cancer. *J Clin Microbiol*. 2008, 46:1570.
97. Abdulamir AS, Hafidh RR, Mahdi LK, Al-jeboori T, Abubaker F. Investigation Into the controversial association of *Streptococcus gallolyticus* with colorectal cancer and adenoma. *BMC Cancer*. 2009, 9:403.
98. Ferrari A, Botrugno I, Bombelli E, Dominioni T, Cavazzi E, Dionigi P. Colonoscopy is mandatory after-*Streptococcus bovis* endocarditis: a lesson still not Learned. Case report. *World J Surg Oncol*. 2008; 6:49.
99. Schneider D, Liaw L, Daniel C, Athanasopoulos AN, Herrmann M, Preissner KT, et al. Inhibition of breast cancer bone metastasis and cell adhesion by the extracellular adherence protein of *Staphylococcus aureus*. *Biochem Biophys Res Commun*. 2007, 357:282-8.
100. AJ Edey, Bentley PG, Garrett JP, Liebmann RD. Ductal breast carcinoma Presenting with methicillin-resistant *Staphylococcus aureus* mastitis. *Breast J*. 2005, 11:491-2.
101. Ma Z, Liu L, Zhang F, Yu M, Wang K, Luo J, et al. Human papillomavirus type 16 exists in bacteria isolated from cervical cancer biopsies. *J Int Med Res* 2009; 37:1065-74.
102. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. *Am J Pathol*. 1999, 155:2067-76.
103. Yonemori K, Sumi M, Fujimoto N, Ito Y, Imai A, Kagami Y, et al. Progastrin-releasing peptide as a factor Predicting the Incidence of brain metastasis in Patients WITH SMALL cell lung carcinoma with limited disease prophylactic cranial irradiation Receiving. *Cancer*. 2005, 104:811-6.
104. Prelipcean CC, Mihai C, Gogalniceanu P, Mitrica D, Drug VL, Stanciu C. Manifestations of *Helicobacter pylori* Extragastric Infection. *Rev Med Chir Soc Med Nat Iasi*. 2007, 111:575-83.
105. Theoharides TC. Mast cells and pancreatic cancer. *N Engl J Med* 2008; 358:1860-

1.

106. Kountouras J, Zavos C, Diamantidis MD, Deretzi G, Grigoriadis N, Tsapournas G, et al. A concept of *Helicobacter pylori* and mast cells secrete stress-'Potential Involvement in brain metastases. *J Neuroimmunol*. 2009, 209:121-2.
107. Leverkus M, Finner AM, Pokrywka A, Franke I, Gollnick H. Metastatic squamous cell carcinoma of the ankle in long-standing untreated acrodermatitis chronica atrophicans. *Dermatology*. 2008, 217:215-8.
108. Verma V, Shen D, Sieving PC, Chan CC. The role of infectious agents in the etiology of ocular adnexal neoplasia. *Surv Ophthalmol*. 2008, 53:312-31.
109. Chan CC, Shen D, Mochizuki M, Gonzales JA, Yuen HK, Guex-Crosier Y, et al. Detection of *Helicobacter pylori* and *Chlamydia pneumoniae* genes in primary orbital lymphoma. *Trans Am Ophthalmol Soc* 2006; 104:62-70.
110. Lee SB, Yang JW, Kim CS. The conjunctival MALT lymphoma association entre and *Helicobacter pylori*. *Br J Ophthalmol*. 2008, 92:534-6.
111. Chanudet E, Zhou Y, Bacon CM, Wotherspoon AC, Müller-Hermelink HK, Adam P, et al. *Chlamydia psittaci* is variably associated with ocular adnexal MALT lymphoma in Different Geographical regions. *J Pathol*. 2006, 209:344-51.
112. Aigelsreiter A, Leitner E, Deutsch AJ, Kessler HH, Stelzl E, Beham-Schmid C, et al. MALT Lymphomas *Chlamydia psittaci* in ocular adnexals of: the Austrian experience. *Leuk Res* 2008; 32:1292-4.
113. Vargas RL, Fallon E, Felger RE, Friedberg JW, Arbin AA, Andersen AA, et al. Is There an ocular adnexal lymphoma association entre and Infection with *Chlamydia psittaci*? The University of Rochester experience. *Leuk Res* 2006, 30:547-51.
114. Liu YC, Ohyashiki JH, Ito Y, Iwaya K, Serizawa H, Mukai K, et al. *Chlamydia psittaci* in ocular adnexal lymphoma: Japanese experience. *Leuk Res* 2006, 30:1587-9.
115. Quint KD, de Koning MN, DT Geraets, Quint WG, Pirog EC. Comprehensive analysis of human papillomavirus and *Chlamydia trachomatis* in in-situ and invasive cervical adenocarcinoma. *Gynecol Oncol*. 2009, 114:390-4.
116. JP Carvalho, Carvalho FM. Is *Chlamydia*-infected tubal fimbria the origin of ovarian cancer?. *Med Hypotheses*. 2008, 71:690-3.
117. Xu Y, Stange-Thomann N, Weber G, Bo R, Dodge S, David RG, et al. Pathogen discovery from human tissue by sequence-based computational subtraction. *Genomics*. 2003, 81:329-35. Erratum in: *Genomics*. 2003, 81:648
118. Feng H, Taylor JL, Benos PV, Newton R, Waddell K, Lucas SB, et al. Human transcriptome subtraction by using short sequence tags to search for tumor viruses in conjunctival carcinoma. *J Virol*. 2007; 81:11332-40.
119. Duncan CG, Leary RJ, Lin JC, Cummins J, Di C, Schaefer CF, et al. Identification of microbial DNA in human cancer. *BMC Med Genomics*. 2009, 8:2-22.
120. Sleator RD, Shortall C, Hill C. Metagenomics. *Lett Appl Microbiol*. 2008, 47:361-6.
121. WJ Ansorge. Next-generation DNA sequencing techniques. *N Biotechnol*. 2009, 25:195-203.
122. Avila M, Ojcius DM, Yilmaz O. The oral microbiota: Living With a permanent guest. *DNA Cell Biol* 2009, 28:405-11.
123. Ventura M, Turrone F, Canchaya C, Vaughan EE, O'Toole PW, van Sinderen D. Microbial diversity in the human intestine and novel insights from Metagenomics. *Front Biosci*. 2009, 14:3214-21.

124. Muyz G, De Waal EC, Uitterlinden AG. Profiling of complex microbial denaturing gradient Populations by gel electrophoresis analysis of polymerase chain reaction-amplified genes coding for 16S rRNA. *Appl Environ Microbiol.* 1993, 59:695-700.
125. Schwieger F, Tebbe CC. A new approach to using PCR-single-strand conformation polymorphism for 16S-rRNA gene-based microbial community analysis. *Appl Environ Microbiol.* 1998, 64:4870-6.
126. Peix A, Rivas R, Velázquez E, Mateos PF, Martínez-Molina E, Munoz-Herrera A, et al. Application of horizontal staircase electrophoresis in agarose MiniGels to the random intergenic spacer analysis of clinical samples. *Electrophoresis.* 2005, 26:4402-10.
127. Scanlan PD, Shanahan F, Marchesi JR. Culture-independent analysis of the human distal desulfovibrios in healthy colon of, colorectal cancer and polypectomized Individuals. *FEMS Microbiol Ecol.* 2009, 69:213-21.
128. Lampe JW. The Human Microbiome Project: Getting to the guts of the matter in cancer epidemiology. *Cancer Epidemiol Biomarkers Prev* 2008; 17:2523-32.
129. Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with Alterations in the microbiome. *Gastroenterology.* 2009, 137:588-97.
130. Van Vliet MJ, WJ Tissing, Dun CA, Meessen NE, Kamps WA, De Bont ES, et al. Chemotherapy Treatment in Pediatric Patients with acute myeloid leukemia Receiving Prophylaxis antimicrobial leads to a relative Increase of colonization with pathogenic bacteria in the Potentially gut. *Clin Infect Dis.* 2009, 49:262-70.
131. Jakobsson HE, Jernberg C, Andersson AF, Karlsson Sjölund-M, Jansson JK, Engstrand L. Treatment Short-term antibiotic have differing long-term Impacts on the human gut microbiome and throat. *PLoS ONE.* 2010, 5: e9836.
132. Van Vliet MJ, Harmsen HJ, De Bont ES, Tissing WJ. The role of intestinal microbiota in the Development and Severity of chemotherapy-induced mucositis. *PLoS Pathogen.* 2010; 6: e1000879.

Velázquez, Encarnaa; Peix Álvarob, Gomez-Alonso, Albertoc

a Department of Microbiology and Genetics, University of Salamanca, Salamanca, Spain

bIRNASA-CSIC, Salamanca, Spain

cDepartamento of Surgery, University of Salamanca, Salamanca, Spain

